Used in pharmaceutical research as a potent and selective agonist of the GPR119 receptor, which is involved in glucose homeostasis and insulin secretion. This compound shows promise in the development of treatments for type 2 diabetes due to its ability to enhance glucose-dependent insulin release and stimulate incretin hormone secretion. It also exhibits favorable pharmacokinetic properties, making it a valuable lead compound in metabolic disease drug discovery. Additionally, it has been studied for its potential in reducing food intake and body weight, suggesting possible applications in obesity management.